What are the indications and dosages of cefixime (Cefixime) for adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefixime Indications and Dosing

Cefixime is no longer recommended as first-line therapy for gonorrhea due to rising resistance, but remains FDA-approved for urinary tract infections, otitis media, pharyngitis/tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea (with significant caveats). 1, 2

FDA-Approved Indications

Adults

  • Uncomplicated urinary tract infections: 400 mg orally once daily 2
  • Acute exacerbations of chronic bronchitis: 400 mg orally once daily 2
  • Pharyngitis and tonsillitis: 400 mg orally once daily 2
  • Uncomplicated gonorrhea (cervical/urethral): 400 mg orally as a single dose 2

Pediatric Patients (≥6 months old)

  • Standard dosing: 8 mg/kg/day orally, given as a single daily dose or divided into two doses 2
  • Maximum daily dose: 400 mg 2
  • Available formulations: Oral suspension (100 mg/5 mL or 200 mg/5 mL) for children; capsules (400 mg) for adults 2

Critical Limitations for Gonorrhea Treatment

The CDC explicitly recommends AGAINST using cefixime as first-line therapy for gonorrhea since 2012. 1, 3, 4

Why Cefixime Fell from First-Line Status:

  • Inferior cure rates: Only 97.1-97.4% for urogenital/anorectal gonorrhea versus 99.1% for ceftriaxone 1, 3
  • Poor pharyngeal efficacy: Only 91% cure rate for pharyngeal gonorrhea, below the 95% threshold required for first-line therapy 4, 5
  • Rising resistance: Isolates with elevated MICs increased from 0.1% (2006) to 1.5% (2011) nationally, with 3.8% among MSM by 2011 5
  • Lower bactericidal levels: Provides less sustained blood levels than ceftriaxone 125 mg IM 1, 3

Current CDC Recommendations for Gonorrhea:

  • First-line: Ceftriaxone 250 mg IM plus azithromycin 1 g orally 1, 4
  • Alternative (only when ceftriaxone unavailable): Cefixime 400 mg orally plus azithromycin 1 g orally, with mandatory test-of-cure at 1 week 1, 4, 5
  • Never use cefixime alone without azithromycin or doxycycline co-treatment 5
  • Avoid for pharyngeal infections given suboptimal 91% efficacy 4

Dosing Adjustments

Renal Impairment

  • Creatinine clearance <60 mL/min: Dose adjustment required 2
  • Creatinine clearance 21-60 mL/min: 75% of standard dose (300 mg daily for adults) 2
  • Creatinine clearance ≤20 mL/min or hemodialysis: 50% of standard dose (200 mg daily for adults) 2

Special Populations

  • Pregnancy: Use only if clearly needed (Category B) 2
  • Nursing mothers: Consider discontinuing nursing temporarily during treatment 2
  • Infants <6 months: Safety and efficacy not established 2
  • Elderly: No specific dose adjustment needed, but monitor renal function 2

Common Pitfalls to Avoid

  1. Using cefixime as monotherapy for gonorrhea: Always combine with azithromycin 1 g orally or doxycycline 100 mg twice daily for 7 days 1, 5
  2. Treating pharyngeal gonorrhea with cefixime: Use ceftriaxone instead due to 91% vs >95% cure rates 4, 5
  3. Forgetting test-of-cure: Mandatory at 1 week when cefixime is used for gonorrhea 1, 4
  4. Ignoring geographic resistance patterns: Higher resistance in Western U.S. and among MSM populations 3, 5

Adverse Effects

  • Most common: Diarrhea (16%), nausea (7%), loose stools (6%), abdominal pain (3%), dyspepsia (3%), vomiting 2
  • Gastrointestinal effects: Usually mild-to-moderate, transient, occur in first few days of treatment 6, 7
  • Hypersensitivity: Rare but can include shock and fatalities; discontinue if reaction occurs 2
  • Clostridium difficile-associated diarrhea: Evaluate if diarrhea develops during or after treatment 2

Drug Interactions

  • Carbamazepine: Elevated levels reported with concomitant use 2
  • Warfarin/anticoagulants: Increased prothrombin time with or without bleeding 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cefixime Treatment Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cefixime Indications and Limitations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cefixime Cure Rate for Gonorrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Safety profile of cefixime.

The Pediatric infectious disease journal, 1987

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.